Hepatitis C: Coffee and More Coffee

Also See;

The Health Benefits Of Coffee

...

Coffee Is A Good Thing Folks

..

In August of 2010 data from a case-control study showed that: moderate coffee consumption significantly reduced the risk of HCC by almost half in chronic HBV.

,

In November of this year at the AASLD meeting in Boston a presentation evaluated the relationship between drinking coffee and the response to HCV anti-viral treatment .

.

From NATAP: Coffee is associated with virologic response in chronic Hepatitis C: Findings from the Hepatitis C Long - Term Treatment against Cirrhosis Trial (HALT - C) ..

The Conclusion: Pre-treatment coffee intake was independently associated with improved virologic response during peginterferon alfa-2a and ribavirin in the HALT-C trial.

"daily coffee consumption of 3 or more cups was associated with 25.8% SVR vs 20.7% for 1- less then 3 cups and 12.7% for less then 1 cup and these are all statistically significant. Coffee increased EVR & week20 responses too"

Check out full data.

.

A study from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), published in the January 2010 issue of Hepatology; has shown that in people with chronic hepatitis C virus who drink about two and a quarter cups of coffee (with caffeine) daily had milder liver fibrosis. However, researchers found that other beverages containing caffeine did not have the same effects.

Full Text

.

The Dec 8th 2010 Abstract below suggests greater than three cups of coffee is associated with reduced histological activity .

Drink Up !

.

, Association Of Caffeine Intake and Histological Features of Chronic Hepatitis C.

J Hepatol. 210 Dec 8.Costentin CE, Roudot-Thoraval F, Zafrani ES, Medkour F, Pawlotsky JM, Mallat A, Hézode C.

AP-HP, Service d'Hépatologie et de Gastroentérologie, Groupe Hospitalier Henri Mondor-Albert Chenevier, Créteil, 94000 France.

AbstractRational The severity of chronic hepatitis C (CHC) is modulated by host and environmental factors. Several reports suggest that caffeine intake exerts hepatoprotective effects in patients with chronic liver disease.

.

The aim of this study was to evaluate the impact of caffeine consumption on activity grade and fibrosis stage in patients with CHC.

.

Methods 238 treatment-naı¨ve patients with histologically-proven CHC were included. Demographic, epidemiological, environmental, virological and metabolic features were collected, including daily consumptions of alcohol, cannabis, tobacco and caffeine during the six month preceding liver biopsy.

.

Daily caffeine consumption was estimated as the sum of mean intakes of caffeinated coffee, tea and caffeine-containing sodas.

.

Histological activity grade and fibrosis stage were scored according to Metavir. Patients (154 men, 84 women, mean age: 45±11 years) were categorized according to caffeine consumption quartiles: group 1 (less then 225 n="59)," n="57)," n="62)" more then 678 mg/day, n=60).

.

Results

There was a significant inverse relationship between activity grade and daily caffeine consumption: Activity grade more then A2 was present in 78%, 61%, 52% and 48% of patients in group 1, 2, 3 and 4, respectively (p less then 0.001). more then A2 (OR=0.32 (0.12-0.85)).

Caffeine intake showed no relation with the fibrosis stage.

.

Conclusions

Caffeine consumption greater than 408 mg/day (3 cups or more) is associated with reduced histological activity in patients with CHC. These findings support potential hepatoprotective properties of caffeine in chronic liver diseases.

Copyright © 2010. Published by Elsevier B.V.
PMID: 21145804

[PubMed - as supplied by publisher]